Swedish Orphan Biovitrum AB (publ)
STO:SOBI

Watchlist Manager
Swedish Orphan Biovitrum AB (publ) Logo
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Watchlist
Price: 310.8 SEK 0.13% Market Closed
Market Cap: 106.7B SEK
Have any thoughts about
Swedish Orphan Biovitrum AB (publ)?
Write Note

Swedish Orphan Biovitrum AB (publ)
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Swedish Orphan Biovitrum AB (publ)
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Current Portion of Long-Term Debt
kr6.1B
CAGR 3-Years
42%
CAGR 5-Years
133%
CAGR 10-Years
123%
Biogaia AB
STO:BIOG B
Current Portion of Long-Term Debt
kr8.8m
CAGR 3-Years
2%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Current Portion of Long-Term Debt
kr6.4m
CAGR 3-Years
4%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Current Portion of Long-Term Debt
kr152m
CAGR 3-Years
113%
CAGR 5-Years
61%
CAGR 10-Years
25%
Probi AB
STO:PROB
Current Portion of Long-Term Debt
kr20.7m
CAGR 3-Years
9%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
BioArctic AB
STO:BIOA B
Current Portion of Long-Term Debt
kr2.8m
CAGR 3-Years
-27%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Swedish Orphan Biovitrum AB (publ)
Glance View

Market Cap
106.7B SEK
Industry
Biotechnology

Swedish Orphan Biovitrum AB (publ), often known as Sobi, navigates the intricate world of biopharmaceuticals with a singular focus on developing and delivering innovative treatments for rare diseases. Founded in the heart of Scandinavia, Sobi has crafted a unique niche by addressing medical needs that are often overlooked by larger pharmaceutical companies. The company specializes in hematology and immunology, focusing on conditions where it can leverage its expertise to make a tangible difference. With a robust pipeline of biopharmaceutical products, Sobi dedicates itself to research and partnerships that not only drive scientific advancements but also ensure that its therapies reach the global market. This mission aligns with its deep commitment to patients whose conditions lack effective treatments. Sobi’s business model thrives on a blend of strategic acquisitions, rigorous clinical development, and expansive distribution capabilities. By acquiring promising therapies and collaborating with other innovators in the biotech space, it continually expands its product portfolio and market reach. Revenue flows primarily from the sales of these specialized therapies, which command premium pricing due to their targeted nature and the complex manufacturing processes involved. The company also invests significantly in its research and development programs, channeling insights from its interactions with healthcare professionals and patients to optimize its offerings. Through its relentless focus on rare diseases, Sobi not only secures financial returns but also significantly impacts the quality of life for patients, staying true to its foundational ethos.

SOBI Intrinsic Value
380.42 SEK
Undervaluation 18%
Intrinsic Value
Price

See Also

What is Swedish Orphan Biovitrum AB (publ)'s Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
6.1B SEK

Based on the financial report for Sep 30, 2024, Swedish Orphan Biovitrum AB (publ)'s Current Portion of Long-Term Debt amounts to 6.1B SEK.

What is Swedish Orphan Biovitrum AB (publ)'s Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 10Y
123%

Over the last year, the Current Portion of Long-Term Debt growth was 81%. The average annual Current Portion of Long-Term Debt growth rates for Swedish Orphan Biovitrum AB (publ) have been 42% over the past three years , 133% over the past five years , and 123% over the past ten years .

Back to Top